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ABSTRACT
Cytomegalovirus (CMV) disease in candidates for hematopoietic cell transplantation (HCT) is increasingly
observed. Among 22 patients with CMV disease before HCT, the incidence of CMV disease before HCT was
significantly higher in patients with severe underlying immune deficiency syndromes compared with patients
with hematologic malignancies (P < .001). The lung was the most commonly involved site of infection,
followed by the gastrointestinal tract and the retina. Fourteen of 22 patients with CMV disease before HCT
responded to treatment and proceeded to HCT; 8 of 22 did not receive an HCT because of fatal CMV disease
(n  2) or other complications (n  6). Of 14 patients with CMV disease who subsequently underwent HCT,
6 (42%) had CMV disease diagnosed after transplantation despite antiviral prophylaxis or preemptive therapy,
and 1 patient had evidence of persistent CMV disease before day 100 after HCT. This proportion was
significantly higher than that in patients without CMV disease before HCT during the same time period (day 30,
adjusted P  .003; day 100, adjusted P  .02). Thirteen of 14 patients with pretransplantation CMV disease
died a median of 36 days after transplantation (range, 19-399 days; adjusted P  .005 compared with
CMV-seropositive transplant recipients without a history of pretransplantation CMV disease). In summary,
although CMV disease before HCT may be mild and responsive to treatment, it is associated with a high risk
of early CMV disease and death after transplantation.
© 2005 American Society for Blood and Marrow Transplantation
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fNTRODUCTION
Cytomegalovirus (CMV) disease is an important
ause of morbidity and mortality after hematopoietic
ell transplantation (HCT) [1]. Various preventive
trategies have been implemented and have led to a
igniﬁcant reduction in the incidence of CMV disease
nd CMV-related mortality in this patient population.
reventive measures include the use of CMV-negative
r ﬁltered blood products for seronegative patients
2,3] and the administration of prophylactic ganciclo-
ir either to all CMV-seropositive patients at engraft-
ent or as preemptive therapy with the ﬁrst sign of
MV infection [4,5]. Although current strategies of h
36rophylaxis and preemptive therapy are highly effec-
ive in preventing CMV disease in the period after
ngraftment [6,7], CMV disease can still occur before
ngraftment; pre-engraftment CMV disease is associ-
ted with high mortality [8].
Over the past decades, HCT has become standard
herapy for various hematologic malignancies, and the
pectrum of diseases treated with HCT continues to
xpand. In addition, successful transplantation with
nrelated donors and the successful use of nonmyeloa-
lative or reduced-intensity conditioning regimens
ave increased the pool of patients who are considered
or HCT [9]. Also, transplantation of patients with
uman immunodeﬁciency virus infection may become
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CMV before HCT as a Risk for Complications after Transplantation
Bore common in the future [10]. Therefore, more
atients with severe immune deﬁciencies and a pre-
ransplantation medical history of multiple infections
nd intense pretransplantation immunosuppression
re considered for HCT. A recent study reported that
MV disease can occur in patients with hematologic
alignancies undergoing chemotherapy [11]. Agents
hat are associated with a high risk for CMV disease in
atients with hematologic malignancies and lympho-
as (eg, ﬂudarabine and alemtuzumab) are increas-
ngly used [12]. The effect of a history of CMV disease
n outcome after HCT is not known. The purpose of
his retrospective study was (1) to review cases of
MV disease that occurred among patients referred
or HCT between 1986 and 2000 at the Fred
utchinson Cancer Research Center (FHCRC) with
egard to clinical presentation of CMV disease, clini-
al course, and response to treatment and (2) to de-
ermine the outcome of the patients who proceeded to
CT.
ATIENTS AND METHODS
atient Selection
We included patients who had CMV disease and
ere evaluated for HCT at the FHCRC over a
4-year period. The presence of CMV disease was
etermined by biopsy or bronchoalveolar lavage
BAL) before transplantation. All patients had CMV
erologies and a routine chest radiograph performed
s part of their pretransplantation admission examina-
ion. Evaluation for CMV disease before transplanta-
ion was performed only when indicated by the clin-
cal presentation of the patient, eg, as part of a fever
orkup or when the patient presented with respira-
ory symptoms and/or an abnormal chest radiograph
efore transplantation. When a patient had fever and
astrointestinal or pulmonary symptoms before HCT,
he evaluation usually included routine chest radiog-
aphy and/or computed tomography of the lung, as
ell as appropriate diagnostic studies (viral cultures,
MV antigen tests, endoscopy with biopsy, BAL, and
pen lung biopsy). The Institutional Review Board at
he FHCRC approved the study.
efinitions
CMV disease was deﬁned as demonstration of
MV in biopsy specimens or BAL by culture, histol-
gy, or immunohistochemistry assays in association
ith clinical signs and symptoms [13,14]. CMV pneu-
onia was diagnosed at autopsy if CMV was isolated
rom lung tissue with concomitant pneumonitis on
istopathologic examination. CMV-related mortality
as deﬁned as death that occurred within 6 weeks
fter diagnosis of CMV disease or when CMV disease
as detected at autopsy [15]. A co-pathogen was de- l
B&MTned as any viral, fungal, bacterial, or parasitic patho-
en that was detected by histopathology, culture, or
mmunoﬂuorescence assay at the same site(s) where
MV was demonstrated.
irologic Testing and Surveillance Cultures
Pretransplantation CMV serologies, tube cul-
ures, ﬂuorescent antibody assays, and shell vial
ultures for CMV were performed as previously
escribed [16,17]. Protocols for obtaining surveil-
ance viral cultures varied during the study period.
efore July 1992, blood, urine, and throat cultures
ere performed before transplantation and weekly
hereafter. After July 1992, routine surveillance
esting was performed weekly starting on day 10
fter transplantation by using the CMV pp65 anti-
enemia assay and blood cultures [16].
ntiviral Prophylaxis and Treatment of CMV
isease
CMV-prevention regimens after HCT varied over
ime. Between January 1986 and June 1992, all CMV-
eropositive recipients of allogeneic marrow received
igh-dose intravenous acyclovir (500 mg/m2 every
hours) as previously described [18]; patients who
ere seropositive for herpes simplex virus (but sero-
egative for CMV) received low-dose intravenous
cyclovir (250 mg/m2 every 12 hours) from day 5
efore transplantation until day 30 after transplanta-
ion. After 1992, all herpes simplex virus–seropositive
atients received low-dose acyclovir prophylaxis. Be-
ween July 1992 and June 1994, patients received
anciclovir prophylaxis or preemptive therapy based
n CMV pp65 antigenemia [19]. Thereafter, a pre-
mptive therapy strategy was used [20,21]. One pa-
ient received prophylactic donor-derived CMV-spe-
iﬁc CD8T cells [22]. CMV disease was treated with
ither ganciclovir or foscarnet, with or without intra-
enous immunoglobulin.
tatistical Analyses
The incidence of pretransplantation CMV disease
mong transplantation candidates with and without
evere combined immunodeﬁciency disease (SCID)
as compared by using the 2-tailed Fisher exact test.
he incidence of CMV viremia and CMV disease was
etermined by cumulative incidence curves. Statistical
omparisons were performed by Cox regression mod-
ls with the likelihood ratio test. Survival after trans-
lantation based on pretransplantation CMV disease
tatus was compared by Kaplan-Meier analysis and the
og-rank test.
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1ESULTS
ncidence of CMV Disease among HCT
andidates
From January 1986 to June 2000, CMV disease
as diagnosed in 22 patients who were referred to the
HCRC for HCT (Figure 1). During this time, 4187
atients underwent allogeneic HCT and 1250 under-
ent autologous HCT at the FHCRC. This yields an
stimated incidence of 0.28% of CMV disease occur-
ing before HCT among allogeneic marrow recipients
t the FHCRC (we did not identify pretransplantation
MV disease in candidates for autologous HCT).
he true incidence of CMV disease may in fact be
lightly higher because patients with a history of CMV
isease diagnosed and treated outside of the FHCRC
ould have escaped our computer-assisted search of
edical ﬁles. In addition, autopsy is performed in only
pproximately 40% to 50% of patients who die before,
uring, or after transplantation; therefore, the precise
ause of death may not have been available on all
atients who died before transplantation. The calcu-
ated incidence of CMV disease did not change over
he study (incidences during three 5-year periods be-
inning in 1985; data not shown). It is interesting to
ote that pretransplantation CMV disease was signif-
cantly (P  .001) more common in HCT patients
ith SCID (2 of 14 patients; 14.3%) than in patients
ho underwent allogeneic HCT for other underlying
iseases (12 of 4173; 0.29%).
haracteristics of CMV Disease in HCT
andidates
Table 1 shows the characteristics of 22 HCT candi-
ates. CMV disease was diagnosed during life in 21
atients and in 1 patient by autopsy. Most of these
atients were referred for HCT to treat a hematologic
alignancy, and 15 had received chemotherapy before
heir evaluation at the FHCRC. One of the 2 children
CMV disease in HCT Candidates
(diagnosed before HCT)
N=22
Patients not Transplanted
N=8
Death due to CMV: 2
Other Death: 3
Unstable Medical Condition: 2
No suitable Donor found: 1
Patients Undergoing HCT  
N=14
Analyzed for Outcome after  
HCT
Figure 1. Patient ﬂowchart.ith SCID was diagnosed with CMV disease 2 months
38fter birth. Twelve patients were neutropenic at the time
f diagnosis. Fourteen patients subsequently underwent
arrow transplantation. Of those, 12 presented with
MV disease 6 months before transplantation, and 2
atients were diagnosed 6 months before transplanta-
ion (.7 and 4 years before transplantation). One of these
patients is the only long-term survivor (of the 22
atients).
reatment and Outcome of CMV Disease in HCT
andidates
The clinical characteristics of CMV disease in
CT candidates are shown in Tables 1 and 2. Most
able 1. Characteristics of 22 Patients with CMV Disease before
CT
Variable
No. (%) of Patients with
Indicated Characteristic
edian age, y (range) 35.2 (8 mo to 66 y)
ale sex 13
nderlying disease
Acute myelogenous leukemia 8
Acute lymphoblastic leukemia 5
Myelodysplastic syndrome 3
T-cell deficiency syndrome
(SCID) 2
Other (NHL, MM, CML) 4
isease status
Remission 2
Advanced or relapse 14
NA 6
reatment of underlying disease
before MT
Chemotherapy 15
Other 7
bsolute neutrophil count at
time of CMV disease
<500 per mm3 12
>500 per mm3 7
Not assessed 3
MV serostatus
Seropositive 19
Seronegative 3
edian day of CMV diagnosis
before transplantation 156 (range, 16 to 1479)
<6 mo 11
>6 mo 2
ite of CMV disease before MT
Lung 20
Gastrointestinal (liver,
stomach) 2
Eye 1
xcretion of CMV before MT
Blood 7
Urine 3
Throat 3
o. of patients who underwent
MT after CMV disease was
diagnosed 14
MV indicates cytomegalovirus; HCT, hematopoeitic cell trans-
plantation; SCID, severe combined immunodeﬁciency disease;
NHL, non-Hodgkin lymphoma; MM, multiple myeloma;
CML, chronic myeloid leukemia; NA, not available; MT, mar-
row transplantation.
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CMV before HCT as a Risk for Complications after Transplantation
Batients presented with pulmonary symptoms. One
atient with SCID had CMV retinitis in addition to
MV pneumonia before marrow transplantation.
hree patients, including the 2 children with SCID,
ad more than 1 episode of CMV disease before
ransplantation (Table 1). Pulmonary signs and
ymptoms varied signiﬁcantly. Twelve of the 20
atients with CMV disease in their lung presented
ith a mild pneumonitis without signiﬁcant hyp-
able 2. CMV Disease before HCT: Clinical Manifestation,
reatment, and Outcome
Variable
No.
Patients
linical signs
Pneumonitis, no hypoxia 12
Pneumonia with hypoxia requiring O2 3
Pneumonia requiring mechanical ventilation 3
Gastrointestinal symptoms 2
Retinitis 1
Asymptomatic pre-HCT workup of abnormal
CXR 2
XR findings
Focal 9
Diffuse 7
Nodular 3
Normal 3*
nvasive co-pathogens (n  11)†
Viral 2
Bacterial 1
Fungal 8
reatment of CMV disease before HCT
Yes 12
No 10
reatment of CMV disease by manifestation
Pneumonia (n  20)
No specific treatment 8
Ganciclovir or foscarnet 6
Ganciclovir or foscarnet  IgG 5
Gastrointestinal disease (n  2)
No specific treatment 2
Ganciclovir or foscarnet 0
Ganciclovir or foscarnet  IgG 0
Other retinitis and viremia (n  2)‡
No specific treatment 0
Ganciclovir or foscarnet 1
Ganciclovir or foscarnet  IgG 1
utcome of treatment of CMV disease
Improved 6
Worsened§ 3
Unclear 3
MV indicates cytomegalovirus; HCT, hematopoietic cell trans-
plantation; CXR, chest radiograph; Ig, immunoglobulin.
Including 2 patients with gastrointestinal disease; the 1 patient with
normal CXR had persistent hypoxemia.
Fungal co-pathogens: aspergillus (n 4), mucor (n 1), Candida (n
1), Pneumocystis carinii (n 1), and unidentiﬁed mold (n 1); viral
co-pathogens: inﬂuenza virus (n  1) and parainﬂuenza virus (n 
1); bacterial co-pathogens: citrobacter and enterococcus (n  1).
Both patients had CMV pneumonia as well.
One patient died before HCT of CMV pneumonia.
Two patients were transferred home after HCT was cancelled, and
1 died 5 days after treatment was begun of bacterial sepsis.xia. Six patients presented with hypoxia, and half p
B&MTf these patients required mechanical ventilation.
wo patients had no clinical symptoms but pre-
ented with abnormal chest radiographic ﬁndings
n routine pretransplantation evaluation. Of the 20
atients with lung disease, 19 patients had abnormal
hest radiograph ﬁndings; the most common was a
ocal pattern, followed by a diffuse and nodular
attern (Table 2). One patient underwent BAL for
ersistent hypoxia despite normal chest radiograph
ndings.
In 12 of the 22 patients, treatment for CMV
isease was initiated with antiviral medication, and
n half of the patients, CMV-speciﬁc immunoglob-
lin was given in addition to either foscarnet or
anciclovir. Neither patient with gastrointestinal
MV disease received speciﬁc antiviral treatment, 1
atient recovered and underwent transplantation 7
ears later, and the other patient had a recurrent
tomach bleed 1 month later, was discharged, and
id not undergo transplantation because of necrotic
one marrow. Eight patients with CMV isolated
rom the lung were also not treated. In 2 patients
he pulmonary inﬁltrates were believed to be of
oninfectious etiology, and in 5 patients the pathol-
gy report deemed the co-pathogen (3 aspergillus, 1
neumocystis carinii pneumonia, and 1 parainﬂuenza)
s the relevant infectious agent, which was treated
ccordingly. Three of these patients responded and
nderwent transplantation, 1 died of relapse, and 1
as transferred back to his original hospital for
reatment of aspergillosis. One patient did not re-
eive treatment because the diagnosis was made
fter he died. Six patients had radiologic or clinical
vidence of a response to treatment. In 3 patients
he response could not be assessed because they
ere discharged home. Three patients worsened
nder treatment: 1 died of CMV pneumonia before
ransplantation, and 1 died of concomitant bacterial
epsis before transplantation. The third patient un-
erwent transplantation but died shortly after HCT
day 19) with persistent CMV pneumonia.
Fourteen patients underwent marrow transplan-
ation, whereas 8 patients could not undergo trans-
lantation for various reasons (Figure 1). These
ncluded 2 patients who were not deemed stable
nough to undergo HCT because of medical com-
lications of the underlying disease (aspergillosis
nd necrotic bone marrow), 1 patient for whom no
onor was found, and 5 patients who died before
ransplantation and within 37 days of their initial
iagnosis of CMV disease. Of note is that 1 of these
atients died of CMV pneumonia, and 1 died during
onditioning with evidence of CMV pneumonia
the diagnosis of CMV disease was made after the
atient died).
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1able 3. Outcome and Management of 14 Patients Who Had CMV Disease before HCT
Patient
No.
Pretransplantation
CMV Disease
(Site, Time
before HCT)
Type of Graft,
HLA Match
Donor
CMV
Serostatus
Year
of HCT
Acute GVHD
(Grade, Day
after HCT)
Treatment of
CMV Disease
before HCT
Day
of GVHD
1 Liver, 7 y Allo/matched NK 1993 NK No NK
2 Lung, 4 y* Allo/matched  1991 3 Yes 9
3 Lung, 43 d Allo/matched  1989 2 No 32
4 Lung, 42 d Allo/matched  1990 3 No 12
5 Esophagus, 43 d Allo/matched  1991 2 No 8
6 Lung, 9 d Allo/matched  1992 0 No No GVHD
7 Lung, 22 d Unrelated  1993 2 Yes 22
8 Lung, 34 d Allo/mismatched  1995 4 Yes 4
9 Lung, 26 d Unrelated  1995 2 Yes 16
10 Lung, 32 d Unrelated  1995 4 No 27
11§ Eye, 28 d
Lung, 31 d
Unrelated  1997 GVHD in utero Yes No GVHD
12 Lung, 10 d Unrelated  1999 2 Yes 3
13 Lung, 21 d Allo/matched  1997 0 No No GVHD
14§ Lung, 57 d Allo/matched  1999 2 Yes 304
MV indicates cytomegalovirus; HCT, hematopoietic cell transplantation; GVHD, graft-versus-host disease; NK, not known; N/A, not
applicable; GI, gastrointestinal; MRSA, methicillin-resistant Staphylococcus aureus; VOD, veno-occlusive disease; NA, not available.
Patient also had CMV viremia 10 months before transplantation.
Developed CMV disease outside of FHCRC; not clear whether treated (day 118, day 391).
Still on CMV prophylaxis at time of death.
Underlying disease was SCID.
Foscarnet treatment was started day 3; discontinued at day 12 because of toxicity (pretransplantation BAL culture became positive onday 3); the case was coded as disease persistence.
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CMV before HCT as a Risk for Complications after Transplantation
Bharacteristics and Outcome of Patients with
retransplantation CMV Disease Who Underwent
CT
Of the 14 patients who underwent HCT, 13
atients underwent transplantation at the FHCRC,
nd 1 patient did so at another institution (only
verall survival information was available for this
atient). Unrelated or HLA-mismatched donor sta-
able 3. Continued.
CMV
Prophylaxis
before
Engraftment
CMV
Prevention
Strategy after
Engraftment or
Treatment
CMV
Excretion
after HCT
CMV Di
after H
(Site, D
K NK NK NK
cyclovir (high
dose)
No Day 61-110
blood,
throat
No
cyclovir (low
dose)
No Day 75
blood,
day 115
throat,
urine
Lung, da
118
cyclovir (high
dose)
No Day 26
throat
Esophag
day 65
stoma
day 39
o No No No
cyclovir (low
dose)
Ganciclovir
prophylaxis
No No
cyclovir (high
dose)
Ganciclovir
prophylaxis
No No
oscarnet Ganciclovir
treatment
No No
oscarnet Ganciclovir
treatment
Day 14
blood
Lung, da
o Ganciclovir
prophylaxis
No No
oscarnet Ganciclovir plus
foscarnet
treatment
Day 16
blood
Lung 
day 16
oscarnet N/A No Lung, da
oscarnet No Day 35
blood
No
oscarnet
(maintenance)
Foscarnet,
ganciclovir
prophylaxis,
CMV-specific
T cells
No Lung, da
239us, antiviral therapy for pretransplantation CMV t
B&MTisease, CMV donor serostatus, graft-versus-host
isease, and posttransplantation use of antivirals did
ot show a statistically signiﬁcant association with
osttransplantation CMV among the patients who
ad pretransplantation disease.
Of the 13 patients with follow-up information, 6
eveloped CMV disease (4 pneumonia, 1 retinitis, and
gastrointestinal disease) at a median of 42 days after
Treatment
of CMV
Disease
after HCT
Time of
Death after
HCT (d)
Cause of
Death
CMV
Implicated
in Cause
of Death
NK 317 Intracranial
bleed
No
Yes Alive Alive N/A
Yes† 134 CMV
pneumonia
Yes
Yes† 399 CMV ulcer
complicated
by GI bleed
and sepsis
Yes
N/A 22 Intracranial
bleed, MRSA
abscesses,
VOD, renal
failure
No
N/A‡ 28 No
N/A 83 Relapse,
pneumonia
No
Yes 32 Pneumonitis,
GVHD
Yes
Yes 21 CMV and
mucor
pneumonia,
GVHD
Yes
N/A‡ 36 No
Yes 36 CMV
pneumonia
Yes
Yes 19 CMV and
aspergillus
pneumonia
Yes
Yes 46 Alveolar
hemorrhage;
CMV and
influenza
pneumonia
Yes
Yes 398 (day 104
after
second
HCT)
Respiratory
failure
Nosease
CT
ay)
y
us,
;
ch,
1
y 17
eye,
y 19
yransplantation (range, 16-239 days). Three of the 6
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1eveloped CMV disease before day 20 after transplan-
ation (Table 3). One additional patient (patient 8;
able 3) had persistent pneumonia throughout the
osttransplantation course, but CMV could not be
etected at autopsy. Nine patients received anti-CMV
reatment after transplantation, either for recurrence
f CMV disease (n 6) or prophylactically at engraft-
ent as part of the prevention strategy (n  3). Once
igure 2. A, The clinical course of patient 14, with underlying disea
nd Epstein-Barr virus lymphoproliferative disease (Table 3). The
g/kg) and 1 infusion of CMV-speciﬁc CD8 and CD4 T-cell li
CT, below the threshold for interaction with CMV-speciﬁc immu
atient remained negative by pp65 antigenemia, viral culture, and pl
he patient had good CD8 cytotoxic T lymphocyte and CD4T-h
nd aspergillus were detected on lung biopsy on day 239 after tran
onor engraftment and continued immunodeﬁciency and therefore
yeloablative HCT, 3 infusions of CD8 CMV-speciﬁc T-cell cl
resence of high-dose steroids for graft-versus-host disease (2 mg/kg
he patient died of respiratory failure of unknown etiology on day 1
n plasma and pp65 antigenemia were negative 2 days before deathhe patients developed CMV viremia, antigenemia, or s
42isease after transplantation, all patients were treated
ith either ganciclovir or foscarnet, including the 3
atients who had not been receiving prophylaxis (all of
hem underwent transplantation before the institution
f CMV prophylaxis at the FHCRC).
One patient (patient 14) with the underlying disease
f SCID (Table 3 and Figure 2) received 4 doses of
onor-derived CMV-speciﬁc CD8 T cells and Ep-
CID, pretransplantation CMV pneumonia, aspergillus pneumonia,
t received antiviral prophylaxis with foscarnet and ganciclovir (5
e patient received low-dose steroids (0.1-0.2 mg/kg) after the ﬁrst
5]. No early CMV disease occurred during T-cell therapy, and the
olymerase chain reaction throughout the ﬁrst 3 months after HCT.
esponses after T-cell infusions (panels B and C, respectively). CMV
tion. Both infections responded to therapy. The patient had poor
ed a second HCT (day 282 after the ﬁrst HCT). After the second
ere given; however, no lasting response could be detected in the
eeks with a subsequent taper of 10% every 5 days; data not shown).
the second transplantation (CMV DNA polymerase chain reactionse of S
patien
nes. Th
nity [3
asma p
elper r
splanta
receiv
ones w
for 2 w
04 aftertein-Barr virus T-cell lines. This patient had aspergillus
a
p
m
d
p
d
t
r
t
w
t
a
e
p
C
M
P
w
c
s
C
d
f
C
(
t
w
1
a
m
H
t
ﬁ
w
t
f
o
D
H
C
t
w
4
F
d
t
t
s
a
p
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BB&MTnd Epstein-Barr virus disease in addition to pretrans-
lantation CMV disease and was therefore given a non-
yeloablative conditioning regimen consisting of low-
ose total body irradiation. Despite extensive
retransplantation CMV disease, no recurrence of CMV
isease or pp65 antigenemia or viremia occurred during
he T-cell therapy. The patient had a CMV disease
ecurrence late after transplantation, after discontinua-
ion of T-cell therapy. Aspergillus disease did not recur
ith continued antifungal treatment.
Only 1 patient survived the transplantation long
erm, whereas 13 patients died within 19 to 399 days
fter marrow transplantation (median, 36 days). Seven
ither died directly of CMV disease or had evidence of
ersistent CMV disease (Table 3).
omparison of CMV Disease and Overall
ortality between Patients with and without
retransplantation CMV Disease
Patients with pretransplantation CMV disease
ere compared with CMV-seropositive allograft re-
ipients who underwent transplantation during the
ame time period: the time to ﬁrst viremia by culture,
MV disease, and death (time to antigenemia was not
etermined because this test was not consistently per-
ormed throughout the study period). Time to ﬁrst
MV viremia by culture was not statistically different
Figure 3A).There was a higher incidence of post-
ransplantation CMV disease among HCT recipients
ith a history of CMV disease (day 30, P  .003; day
00, P  .02; likelihood ratio test; Figure 3B). This
ssociation remained signiﬁcant in a multivariate
odel that controlled for age, underlying disease risk,
LA match, stem cell source, and year of transplan-
ation (day 100: adjusted hazard ratio, 4.5; 95% con-
dence interval, 1.7-12; P  .02; Table 4). Mortality
as also signiﬁcantly different in patients with pre-
ransplantation CMV disease (Figure 3C). This dif-
erence remained signiﬁcant after controlling for
ther factors (Table 5).
ISCUSSION
Patients with a history of CMV disease before
CT have a high risk for serious complications of
MV disease and overall mortality after transplanta-
ion. This poor outcome occurs despite prophylaxis
ith high-dose acyclovir and ganciclovir at engraft-
™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™
igure 3. Comparison of patients with pretransplantation CMV
isease with CMV-seropositive allograft recipients who underwent
ransplantation during the same time period (n 1581) with regard
o (A) CMV viremia by culture, (B) CMV disease, and (C) overall
urvival after HCT. For CMV viremia and disease, data wereCMV Viremia
CMV pretransplant
No CMV pretransplant
CMV Disease
CMV pretransplant
No CMV pretransplant
No CMV pretransplant  
CMV pretransplant  
Survival
A
B
Cvailable for 13 patients; overall survival was calculated for all 14
atients.
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Table 4. Univariate and Multivariate Risk Factors for CMV Disease
Risk factor Comparison n
By Day 30 By Day 100
HR (95% CI)
P
Value
Adjusted HR
(95% CI)
Adjusted
P Value HR (95% CI)
P
Value
Adjusted HR
(95% CI)
Adjusted
P Value
Pretransplantation CMV
disease
No 1581 1.0 .003 1.0 .003 1.0 .02 1.0 .02
Yes 13 12 (3.5, 37) 11 (3.3, 36) 4.6 (1.7, 12) 4.5 (1.7, 12)
Underlying disease CML-CP 364 1.0 .006 1.0 .007 1.0 .003 1.0 .001
Hem. first
remission
141 5.2 (0.95, 28) 6.2 (1.1, 34) 2.0 (1.2, 3.5) 2.5 (1.4, 4.3)
Hem. > first
remission
719 6.9 (1.6, 29) 6.6 (1.6, 28) 2.0 (1.3, 3.0) 2.1 (1.4, 3.1)
Others 370 3.6 (0.75, 17) 3.4 (0.69, 16) 1.5 (0.97, 2.5) 1.7 (1.1, 2.7)
Donor type HLA
matched
821 1.0 .09 1.0 .06 1.0 .31 1.0 .02
Others 773 1.7 (0.91, 3.3) 1.9 (0.97, 3.6) 1.2 (0.88, 1.5) 1.5 (1.1, 2.0)
Donor CMV serostatus Negative 723 1.0 .28 1.0 .39
Positive 868 0.71 (0.38, 1.3) 0.88 (0.67, 1.2)
Recipient age >10 y 0.89 (0.73, 1.1) .24 1.1 (0.97, 1.2) .17 1.2 (1.1, 1.3) .002
Year of transplantation After 7/1992 1003 1.0 .06 1.0 .0006 1.0 <.0001
Before 7/
1992
591 0.51 (0.24, 1.1) 1.6 (1.2, 2.2) 1.8 (1.4, 2.4)
Pretransplantation
invasive aspergillosis
No 1581 1.0 .30 1.0 .45
Yes 13 3.6 (0.49, 26) 1.8 (0.45, 7.3)
Cell source PBSC 115 1.0 .62 1.0 .27
Others 1479 1.4 (0.34, 5.9) 1.4 (0.74, 2.7)
HR indicates hazard ratio; CI, conﬁdence interval; CML-CP, chronic myelogenous leukemia, chronic phase; PBSC, peripheral blood stem cells; HEM, hematologic malignancy.
B.C
.Fries
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Bent or standard postengraftment preemptive therapy
trategies.
Although our retrospective analysis indicates a
uch lower incidence of CMV disease in patients
efore transplantation compared with patients after
ransplantation, the incidence of CMV disease in this
atient population seems to be signiﬁcantly higher
han in the average cancer population [11,23]. These
ndings are consistent with other studies that showed
hat CMV is an important cause of pneumonia in
atients with leukemia, particularly in patients who
ave received increased immunosuppressive agents
uch as ﬂudarabine [24]. Most of our patients (66%)
ad also undergone chemotherapy for their underly-
ng malignancy before their referral to the FHCRC.
n addition, our data suggest that patients with SCID
arry an increased risk of developing serious compli-
ations from CMV disease and should be carefully
valuated for pretransplantation CMV disease. In our
tudy, these patients were both children with a long-
tanding history of CMV infections and, because of
heir underlying inherited T-cell deﬁciency, probably
ever developed protective immunity after primary
MV infection. Except for the 2 children with SCID,
ost patients who presented with CMV disease before
ransplantation were adults and were seropositive at
he time of their initial presentation with CMV dis-
ase, suggesting that CMV disease in most patients is
reactivation of latent CMV infection.
Most of our patients with pretransplantation
MV disease presented with pneumonia. Two thirds
f these patients had no signs of respiratory compro-
able 5. Survival by 1 Year
Risk Factor Comparison n
retransplantation
CMV disease
No 1581
Yes 14
nderlying disease CML-CP 364
Hem. first remission 141
Hem. >first
remission
719
Others 370
onor type HLA matched 821
Others 773
onor CMV serostatus Negative 723
Positive 868
ecipient age >10 y -
ear of transplantation After 7/1992 1003
Before 7/1992 591
retransplantation
invasive aspergillosis
No 1581
Yes 13
ell source PBSC 115
Others 1479
R indicates hazard ratio; CI, conﬁdence interval; CML-CP, chroni
HEM, hematologic malignancy.ise, whereas 3 patients were hypoxic and 3 patients d
B&MTequired mechanical ventilation at the time of diagno-
is. As previously described for CMV pneumonia in
imilar settings, the chest radiograph ﬁndings of pul-
onary inﬁltrates in patients with CMV pneumonia
re not speciﬁc and can range from focal to diffuse [1].
f note, 2 patients had an abnormal chest radiograph
uring their pretransplantation evaluation but had no
ther clinical symptoms. In addition, surveillance cul-
ures were not reliable in predicting CMV disease in
hese patients because only 31% of the patients were
ound to be viremic by culture. Whether antigenemia
r DNA detection methods would have been positive
n these patients is unknown. Thus, CMV disease may
resent atypically, and clinical signs may be mild in
ransplant candidates.
Half of our patients were simultaneously infected
ith other pathogens, and in 5 cases the patients were
reated only for the other pathogen. It is virtually
mpossible to establish the causative role of a partic-
lar pathogen in a setting of polymicrobial infections,
nd even histopathologic evaluation can underesti-
ate the relevance of a pathogen. For instance, 1 of
ur patients was diagnosed by histopathology as hav-
ng predominately pulmonary aspergillosis, and,
ence, the positive CMV in the BAL was not treated.
his patient became viremic after transplantation and
ied eventually of CMV pneumonia.
In the patients who underwent transplantation af-
er pretransplantation CMV disease, outcome was ex-
remely poor despite a variety of prevention strategies.
his was conﬁrmed in multivariate statistical models
hat controlled for other factors associated with CMV
R (95% CI)
P
Value
Adjusted HR
(95% CI)
Adjusted
P Value
1.0 .003 1.0 .005
.9 (1.6, 5.2) 2.9 (1.5, 5.4)
1.0 <.0001 1.0 <.0001
.2 (0.85, 1.8) 1.6 (1.1, 2.4)
.8 (3.0, 4.8) 4.0 (3.2, 5.1)
.5 (1.9, 3.3) 2.8 (2.2, 3.7)
1.0 <.0001 1.0 <.0001
.6 (1.4, 1.9) 1.9 (1.6, 2.2)
1.0 .97
.0 (0.86, 1.2)
.1 (1.0, 1.1) .004 1.2 (1.1, 1.2) <.0001
1.0 .49 1.0 .01
.1 (0.91, 1.2) 1.2 (1.0, 1.4)
1.0 .009 1.0 .03
.6 (1.4, 4.9) 2.3 (1.2, 4.3)
1.0 .09 1.0 .17
9 (0.61, 1.0) 0.81 (0.61, 1.1)
genous leukemia, chronic phase; PBSC, peripheral blood stem cells;H
2
1
3
2
1
1
1
1
2
0.7
c myeloisease and mortality. It is interesting to note that the
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1ffect of pretransplantation CMV disease on mortality
eemed larger than could be explained by posttrans-
lantation CMV disease. This could be due to the
ndirect effects of CMV disease (eg, increased bacte-
ial and fungal infections), which have been shown to
ffect mortality [25]. It is also noteworthy that results
re poor despite apparent treatment success before
ransplantation in most patients. This is different from
ecent results with pretransplantation invasive as-
ergillosis and respiratory syncytial virus infection in
he HCT setting [26,27]. For instance, patients with
dequately treated invasive aspergillosis before trans-
lantation do not seem to have a posttransplantation
urvival disadvantage when compared with patients
ho did not have pretransplantation invasive aspergil-
osis [26]. This, in addition to the fact that the mor-
ality disadvantage of pretransplantation CMV disease
ersisted after controlling for other predictors of mor-
ality, suggests that there may a severe virus-speciﬁc
mmunodeﬁciency in these patients.
Because these patients were treated over more
han a decade, management was not consistent, but
ost patients received what are regarded as standard
revention strategies, including high-dose acyclovir
rom the start of conditioning and/or ganciclovir at
ngraftment or pp65 antigenemia-guided preemptive
herapy. Despite this, a high CMV disease rate oc-
urred, and all patients but 1 died. A multivariate
nalysis also accounted for changes in supportive care
ractices (Tables 4 and 5). Unfortunately, we do not
ave information in all patients regarding whether
MV infection cleared entirely before patients were
llowed to start conditioning. The relatively early
ime of recurrence suggests that CMV was insufﬁ-
iently treated at the time of transplantation. It is
oteworthy that the only long-term survivor pre-
ented 10 months before transplantation, and his
ransplantation was postponed; this allowed proper
ime for treatment.
One child with SCID and complicated pretransplan-
ation CMV disease received CMV-speciﬁc T-cell ther-
py throughout the ﬁrst months after transplantation.
o CMV antigenemia, DNAemia, or disease was de-
ected during T-cell therapy and maintenance-dose an-
iviral prophylaxis. Similar antiviral prophylaxis did not
revent CMV reactivation in other patients of this co-
ort (Table 3), and CMV infection is expected to occur
fter nonmyeloablative HCT [9]. Recurrence of CMV
isease occurred after discontinuation of T-cell therapy
Figure 3). Although we had only a single case in this
eries, this case raises the intriguing possibility that T-
ell therapy may be the best option for prevention in
hese patients. Adoptively transferred T cells have been
hown in recent studies to have antiviral activity [28], and
ovel techniques of rapid expansion make this approach
ore readily available [29,30]. Another preventive op-ion suggested by this case is the use of nonmyeloablative a
46onditioning regimens. However, it should be pointed
ut that the proposed mechanism of early protection
rom CMV disease after nonmyeloablative regimens, ie,
he persistence of host immunity [31], is unlikely to work
n SCID patients who are unable to generate protective
mmunity even before undergoing transplantation. Con-
istent with this, our patient did not have CMV-speciﬁc
esponses before the T-cell infusion.
In conclusion, CMV disease before HCT is asso-
iated with an exceedingly high mortality in myeloa-
lative allogeneic transplant recipients. These poor
esults suggest that more aggressive management of
hese cases is needed. The early recurrence of CMV
isease after HCT warrants treatment of any pretrans-
lantation CMV disease (including mild cases). This
hould include induction treatment with ganciclovir
r foscarnet until resolution of signs and symptoms,
ncluding negative pp65 antigenemia or polymerase
hain reaction testing. It also seems advisable to delay
ransplantation until the disease is sufﬁciently treated
r, if this cannot be accomplished, not to perform the
ransplantation. Maintenance therapy should be con-
inued until the start of conditioning. Donor-derived
MV-speciﬁc T-cell therapy should be strongly con-
idered [22,28]. Although this treatment is not yet
idely available and may not be feasible if the donor is
MV seronegative or unrelated, recent technologic
dvances could lead to timely production of speciﬁc
ellular therapy. Alternatively, foscarnet prophylaxis
ith a minimum dose of 60 mg/kg twice daily until
ngraftment seems justiﬁed [32]. After engraftment,
ither ganciclovir prophylaxis or twice-weekly CMV
onitoring and preemptive therapy should be given
Centers for Disease Control and Prevention guide-
ines recommend only weekly testing in allograft re-
ipients [33]). In patients who cannot receive foscarnet
rophylaxis at the start of conditioning regimen, high-
ose intravenous acyclovir in combination with twice-
eekly plasma polymerase chain reaction testing for
he ﬁrst 2 months after transplantation with highly
ensitive assays and a low threshold for preemptive
reatment (eg, 100 copies per milliliter) may be an
lternative [34]. Antifungal prophylaxis with agents
ith antimold activity also seems advisable. This study
lso underscores the need for thorough evaluation of
atients before transplantation. Patients with pulmo-
ary or gastrointestinal signs or symptoms should be
valuated by BAL or biopsy, respectively, for possible
MV disease. Patients with T-cell immunodeﬁcien-
ies should also receive an ophthalmic examination to
xclude CMV retinitis and should be tested for vire-
ia. Pretransplantation detection of CMV in blood is
lso advised in patients who are severely lymphocyto-
enic because of treatment with ﬂudarabine, alemtu-
umab, or similar agents [11,12]. Whether nonmy-
loablative conditioning regimens require similarly
ggressive approaches is unknown.
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